News ReleaseView printer-friendly version << Back
Pacira Pharmaceuticals, Inc. Reports $10.4 Million in First Quarter EXPAREL Revenue and Full First Quarter 2013 Financial Results
Company Will Host Conference Call Today at
“We saw a solid quarter in what was the fourth quarter of our EXPAREL
Recent Highlights and Upcoming Events
EXPAREL Commercialization: In the first quarter ended
March 31, 2013, EXPAREL sales totaled $10.4 million, up from $7.8 millionin the fourth quarter of 2012. As of March 31, 2013, 1,065 accounts ordered EXPAREL, compared to 819 accounts as of December 31, 2012. Of these, 308 accounts ordered EXPAREL six times or more and 175 accounts ordered 10 times or more. Pacira continues its steady expansion since launch with an average of 22 new customers per week as of March 31, 2013.
- EXPAREL as Part of a Multimodal Approach to Postsurgical Pain Management: Recently published national and regional analyses of more than 400,000 patients receiving opioids for postsurgical pain management show that patients who experienced opioid-related adverse events (ORAEs) had longer lengths of hospital stay, higher costs of care, greater rates of 30-day readmission to the hospital and a significantly increased risk of mortality. Although opioids have long been the mainstay of postsurgical pain control, these analyses are part of a growing body of evidence that suggests the need to re-examine the benefit-risk profile of an opioid-centric pain management paradigm and to explore a multimodal approach that uses alternative modalities to decrease the amount of opioids needed.
- Recent Data Supporting the Utility of EXPAREL Among Surgical Audiences: Last month, Pacira announced results from EXCLAIM, its Phase 4 prospective, observational study, to assess the use of EXPAREL for postsurgical analgesia in patients undergoing four common plastic surgery procedures.
Investor Meetings: Pacira management will be presenting at the
Bank of America Merrill Lynch2013 Health Care Conferenceon May 15, 2013in Las Vegasand will be presenting at the Jefferies 2013 Global Healthcare Conference on June 3, 2013in New York City.
Total revenues for the quarter ended
March 31, 2013were $11.6 millioncompared with $7.8 millionfor the quarter ended March 31, 2012. The increase in revenues was primarily driven by $10.4 millionof net product sales of EXPAREL, which represents the sale of product shipped directly to end-users, including hospitals and ambulatory surgery centers. This was partially offset by a decrease in collaborative licensing and development revenue of $6.2 milliondue to the recognition of deferred revenue during 2012 associated with the termination of certain licensing agreements.
Total operating expenses for the quarter ended
March 31, 2013were $30.2 millioncompared with $18.9 millionfor the quarter ended March 31, 2012. The increase was primarily driven by the cost of EXPAREL product sold. Additionally, clinical development costs increased due to the ongoing pivotal trials of EXPAREL administered as a femoral nerve block for total knee arthroplasty surgery and as an intercostal nerve block for thoracotomy.
Net loss for the quarter ended
March 31, 2013was $23.1 million, or $0.71per share (based on 32.7 million weighted average shares outstanding) compared to $11.9 million, or $0.47per share (based on 25.4 million shares outstanding) for the quarter ended March 31, 2012. The increase in net loss was the result of increased operating expenses and a $3.4 millionloss on early extinguishment of debt recognized during the quarter ended March 31, 2013. As of March 31, 2013, the Company had 33.0 million shares of common stock outstanding.
Pacira ended the first quarter of 2013 with cash and cash equivalents,
restricted cash and short-term investments (“cash”) of
$110.2 million. During the quarter ended March 31, 2013, Pacira closed an offering of $120.0 millionin aggregate principal amount of 3.25 percent convertible senior notes due February 1, 2019.
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the
company’s financial results and recent and upcoming developments today,
A replay of the call will be available approximately two hours after the completion of the call and can be accessed by dialing 1-888-286-8010 (domestic) or 1-617-801-6888 (international), and providing the passcode 60916641. The replay of the call will be available for two weeks from the date of the live call.
The live, listen-only webcast of the conference call can also be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the call.
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.
Forward Looking Statements
Any statements in this press release about our future expectations,
plans and prospects, including statements about our plans and
expectations regarding EXPAREL, and other statements containing the
words “believes,” “anticipates,” “plans,” “expects,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including risks
relating to: the success of our sales and manufacturing efforts in
support of the commercialization of EXPAREL; the rate and degree of
market acceptance of EXPAREL; the size and growth of the potential
markets for EXPAREL and our ability to serve those markets; our plans to
expand the indications of EXPAREL to include nerve block; our plans to
continue to manufacture and provide support services for our commercial
partners who have licensed DepoCyt(e); our commercialization and
marketing capabilities; and other factors discussed in the “Risk
Factors” of our most recent Annual Report on Form 10-K for the fiscal
|Pacira Pharmaceuticals, Inc.|
|Consolidated Statements of Operations|
|(in thousands, except share and per share amounts)|
|Three Months Ended|
|Net product sales||$||10,835||$||446|
|Collaborative licensing and development revenue||243||6,490|
|Cost of revenues||11,391||6,495|
|Research and development||5,905||1,294|
|Selling, general and administrative||12,936||11,152|
|Total operating expenses||30,232||18,941|
|Loss from operations||(18,645||)||(11,137||)|
|Other (expense) income:|
|Loss on early extinguishment of debt||(3,398||)||-|
|Royalty interest obligation||(86||)||(282||)|
|Total other expense, net||(4,935||)||(757||)|
|Loss before income taxes||(23,580||)||(11,894||)|
|Income tax benefit||442||-|
|Net loss per share:|
|Basic and diluted net loss per common share||$||(0.71||)||$||(0.47||)|
|Weighted average common shares outstanding:|
|Basic and diluted||32,709,298||25,367,306|
|Pacira Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheets|
|March 31,||December 31,|
|Cash and cash equivalents, restricted cash and short-term investments||$||110,246||$||42,573|
|Accounts receivable, net||5,243||4,352|
|Prepaid expenses and other current assets||2,740||1,920|
|Total current assets||128,989||60,922|
|Fixed assets, net||41,130||39,116|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current portion of royalty interest obligation||853||823|
|Current portion of deferred revenue||972||972|
|Total current liabilities||12,698||14,156|
|Long-term debt, net of discount||95,857||25,191|
|Royalty interest obligation||723||857|
|Total stockholders' equity||69,792||65,855|
|Total liabilities and stockholders' equity||$||185,241||$||112,054|
Pacira Pharmaceuticals, Inc.
Jessica Cho, 973-254-3574
Pure Communications, Inc.
Susan Heins, 864-286-9597